Phaseline

Targets › TOPO2A

TOPO2A: drug programs, companies and trials

13 programs from 12 companies in 14 trials: 6 Phase 2, 6 Phase 3, 2 Phase 1; Oncology, Other, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: the race on TOPO2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Assistance Publique - Hôpitaux de ParisModified FOLFIRINOX
Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit
TOPO1, TOPO2A, MTHFR, TYMSPhase 3Rectal CancerDec 2026
Sun Yat-sen UniversitymFOLFOXIRI
Multi-drug chemotherapy regimen: oxaliplatin (platinum-based DNA crosslinker), irinotecan
TOPO1, TOPO2A, ERCC1Phase 3Colon Cancer Stage IIDec 2026
Children's Oncology GroupBleomycin Sulfate
Topoisomerase II inhibitor; DNA-damaging chemotherapy agent
TOPO2APhase 3Childhood Extracranial Germ Cell TumorJun 2027
Dominik Paul ModestmFOLFOXIRI
Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit
TOPO1, TOPO2APhase 3Colorectal CancerNov 2027
Azienda Ospedaliera Universitaria Integrata VeronaFOLFOX
Combination of 5-fluorouracil, leucovorin, and oxaliplatin; topoisomerase II inhibitor and
TOPO2APhase 3Oligometastatic Gastric AdenocarcinomaSep 2028
Sixth Affiliated Hospital, Sun Yat-sen UniversityOxaliplatin With S-1 (SOX) Combined H. Pylori Eradication
Topoisomerase II inhibitor (oxaliplatin, platinum-based chemotherapy) combined with antime
TOPO2APhase 2Chemotherapy EffectDec 2026
Seoul National University Bundang HospitalmFOLFOX/mFOLFIRI
Combination of fluorouracil with oxaliplatin and irinotecan
TOPO1, TOPO2APhase 2Biliary Cancer MetastaticApr 2027
Sun Yat-sen UniversityTeniposide
Topoisomerase II inhibitor
TOPO2APhase 2Small-cell Lung CancerMay 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineTEAM regimen
High-dose chemotherapy conditioning regimen combining thiotepa (alkylating agent), etoposi
TOPO2APhase 2Lymphoma Patients With High-risk of Central Nervous System RelapseMar 2028
Institut du Cancer de Montpellier - Val d'Aurellemodified FOLFIRINOX regimen
Combination chemotherapy: irinotecan (topoisomerase I inhibitor), oxaliplatin (platinum cr
TOPO1, TOPO2A, ERCC1Phase 2Locally Advanced Malignant NeoplasmSep 2029
Hospital Universitario Doctor Pesetmodified TPF
Modified docetaxel-cisplatin-fluorouracil chemotherapy combination
TOPO2A, TOPO1Phase 2Locally Advanced Head and Neck Squamous Cell Carcinoma–
GSKGepotidacin
Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor
TOPO2APhase 1Urinary Tract InfectionsMay 2027
University of Colorado, DenverNALIRIFOX
Combination of liposomal irinotecan (topoisomerase I inhibitor), 5-fluorouracil (thymidyla
TOPO1, TOPO2A, TYMSPhase 1Pancreatic Ductal Adenocarcinoma (PDAC)Jul 2028

Conditions

Oligometastatic Gastric Adenocarcinoma (2) Locally Advanced Head and Neck Squamous Cell Carcinoma (1) Rectal Cancer (1) Biliary Cancer Metastatic (1) Chemotherapy Effect (1) Pancreatic Ductal Adenocarcinoma (PDAC) (1) Urinary Tract Infections (1) Lymphoma Patients With High-risk of Central Nervous System Relapse (1) Small-cell Lung Cancer (1) Colon Cancer Stage II (1) Childhood Extracranial Germ Cell Tumor (1) Colorectal Cancer (1)

Modalities

small molecule (9), mixed (2)

Companies

Sun Yat-sen University (2) Hospital Universitario Doctor Peset (1) Assistance Publique - Hôpitaux de Paris (1) Seoul National University Bundang Hospital (1) Sixth Affiliated Hospital, Sun Yat-sen University (1) University of Colorado, Denver (1) GSK (1) Azienda Ospedaliera Universitaria Integrata Verona (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Children's Oncology Group (1) Dominik Paul Modest (1) Institut du Cancer de Montpellier - Val d'Aurelle (1)

Related targets

TOPO1 (7) TYMS (2) ERCC1 (2) MTHFR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.